Publication Name	World Journal of Gastroenterology
Manuscript ID	99443
Country	China

Received	2024-08-20 00:59
Peer-Review Started	2024-07-22 17:00
To Make the First Decision
Return for Revision	2024-10-23 01:43
Revised	2024-11-04 10:15
Second Decision	2024-11-25 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-25 06:21
Articles in Press	2024-11-25 06:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-30 06:03
Publish the Manuscript Online	2024-12-18 07:36

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Current status of drug therapy for chronic hepatitis B
Manuscript Source	Invited Manuscript
All Author List	Chuang Jiang, Zhi-Hong Zhang and Jia-Xin Li
ORCID	Author(s) ORCID Number Jia-Xin Li http://orcid.org/0009-0005-8538-5900
Funding Agency and Grant Number	Funding Agency Grant Number the Project of Guizhou Provincial Department of Science and Technology Qiankehechengguo-LC[2024]109
Corresponding Author	Jia-Xin Li, Assistant Professor, MD, Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. lijiaxin@scu.edu.cn
Key Words	Chronic hepatitis B; Hepatitis B virus; Anti virus; Drug treatment; Therapy
Core Tip	Chronic hepatitis B poses a serious threat to human health, and drug treatment is the most important method. The purpose of treatment is to sustainably inhibit virus replication and even achieve clinical cure, prevent or slow down disease progression, and reduce the incidence of cirrhosis and hepatocellular carcinoma. The widely used drugs at present are interferon and nucleoside/nucleotide analogue. On the premise of ensuring the efficacy, increasing drug safety and reducing side effects is an important research direction of anti-hepatitis B virus treatment.
Publish Date	2024-12-18 07:36
Citation	<p>Jiang C, Zhang ZH, Li JX. Current status of drug therapy for chronic hepatitis B. <i>World J Gastroenterol</i> 2025; 31(2): 99443</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i2/99443.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i2.99443

Full Article (PDF)	WJG-31-99443-with-cover.pdf
Manuscript File	99443_Auto_Edited_100019.docx
Answering Reviewers	99443-answering-reviewers.pdf
Audio Core Tip	99443-audio.mp3
Conflict-of-Interest Disclosure Form	99443-conflict-of-interest-statement.pdf
Copyright License Agreement	99443-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99443-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	99443-non-native-speakers.pdf
Peer-review Report	99443-peer-reviews.pdf
Scientific Misconduct Check	99443-scientific-misconduct-check.png
Scientific Editor Work List	99443-scientific-editor-work-list.pdf
CrossCheck Report	99443-crosscheck-report.pdf